381 related articles for article (PubMed ID: 11085525)
1. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
2. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Arnold CN; Goel A; Boland CR
Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
[TBL] [Abstract][Full Text] [Related]
3. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
4. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
6. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
7. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
8. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
Deng G; Chen A; Hong J; Chae HS; Kim YS
Cancer Res; 1999 May; 59(9):2029-33. PubMed ID: 10232580
[TBL] [Abstract][Full Text] [Related]
9. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
10. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
11. [Methylation of mismatch repair gene (MMR) in primary hepatocellular carcinoma].
Zhang CJ; Li HM; Yau LM; Suen KW; Zhou GY; Yu F; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2004 Oct; 33(5):433-6. PubMed ID: 15498213
[TBL] [Abstract][Full Text] [Related]
12. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
13. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
Deng G; Chen A; Pong E; Kim YS
Oncogene; 2001 Oct; 20(48):7120-7. PubMed ID: 11704838
[TBL] [Abstract][Full Text] [Related]
14. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
15. [Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro].
Wu F; Hu CH
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):349-53. PubMed ID: 21875463
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic approaches to cancer therapy.
Plumb JA; Steele N; Finn PW; Brown R
Biochem Soc Trans; 2004 Dec; 32(Pt 6):1095-7. PubMed ID: 15506976
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1.
Fleisher AS; Esteller M; Harpaz N; Leytin A; Rashid A; Xu Y; Liang J; Stine OC; Yin J; Zou TT; Abraham JM; Kong D; Wilson KT; James SP; Herman JG; Meltzer SJ
Cancer Res; 2000 Sep; 60(17):4864-8. PubMed ID: 10987299
[TBL] [Abstract][Full Text] [Related]
20. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
